Zuclopenthixol LA-Haloperidol

Zuclopenthixol
long acting
Type Antipsychotic
Group Thioxanthenes
links
PubChem 5311507
PubMed Zuclopenthixol
Kompas (Dutch) Zuclopenthixol
Wikipedia Zuclopenthixol
Haloperidol
Type Antipsychotic
Group Butyrophenones
links
ATC-code N05AD01
Medscape Haloperidol
PubChem 3559
PubMed Haloperidol
Drugs.com haloperidol
Kompas (Dutch) Haloperidol
Wikipedia Haloperidol

Switch medication from Zuclopenthixol_LA to Haloperidol.

Nietinrijdenbord.png Stop Zuclopenthixol_LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Haloperidol
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[5]
    StopDepotStartOral.jpg
Nietinrijdenbord.png — Zuclopenthixol_LA
Eenrichtingbord.png — Haloperidol


  1. ↑ WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
  2. ↑ 2.02.12.2 KNMP; Informatorium Medicamentorum 2015; Monografie "haloperidol" (Dutch)
  3. ↑ 3.03.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
  4. ↑ 4.04.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
  5. ↑ Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.